GABA: How Fermented Foods Could Calm the Brain and Body

γ-Aminobutyric acid, better known as GABA, has long been famous as the brain’s main inhibitory neurotransmitter, the molecule that quiets overactive neurons and helps us sleep. But a sweeping new review published in Food Chemistry: X argues that this four-carbon amino acid deserves a much bigger reputation. Drawing on hundreds of peer-reviewed studies from the past decade, the authors present GABA as a systemic regulator that orchestrates nervous, metabolic, and immune functions far beyond the central nervous system, and they make the case that lactic acid bacteria, the same microbes behind yogurt, kimchi, and sourdough, are the most practical route for delivering it through food.

The review’s boldest claim is conceptual: GABA should no longer be viewed purely as a neural signaling molecule but as an endogenous bioactive metabolite with pleiotropic regulatory reach. Evidence links it to the pathophysiology of mood disorders such as major depressive disorder through modulation of excitatory-inhibitory balance and bidirectional gut-brain axis signaling. It also appears to coordinate glucose and lipid metabolism across multiple organs, exert anti-inflammatory effects by modulating immune responses, and reconfigure gut microbiota composition in preclinical studies. This paradigm shift recasts GABA from a brain chemistry curiosity into a multifunctional systemic regulator with therapeutic and nutraceutical potential for functional foods targeting neurological, metabolic, and immunomodulatory health.

The technical heart of the review concerns how lactic acid bacteria actually make GABA. The canonical route is the glutamate decarboxylase, or GAD, system, a conserved acid-resistance mechanism distributed widely in bacteria. Two PLP-dependent decarboxylases, GadA and GadB, convert L-glutamate to GABA through α-decarboxylation, while GadC functions as a glutamate/GABA antiporter handling substrate uptake and product efflux. Crucially, each decarboxylation event consumes an intracellular proton, directly linking GABA production to the maintenance of cytoplasmic pH homeostasis under acidic conditions. This proton-consuming reaction, coupled with GadC antiport, enables the cell to survive fermentation while exporting the synthesized GABA, explaining why the GAD system is both an acid tolerance mechanism and a biosynthetic factory.

Regulation of the system operates at multiple levels. The gad operon is primarily induced by acidic pH through two-component signal transduction systems such as ComDE. Substrate availability and its interaction with GadC positively regulate enzyme activity through allosteric effects. Carbon source limitation and entry into stationary phase frequently enhance productivity. Pyridoxal 5′-phosphate, the cofactor, stabilizes the reaction intermediate by forming a Schiff base at the active center and serves as a critical rate-limiting factor for GAD activity. Metabolic engineering frequently targets these rate-limiting steps: in Levilactobacillus brevis LAB6, the complete gene cluster comprising gadA, gadB, and gadC constitutes the key genetic basis for high yield, and overexpression of gadB or gadC, or co-expression of PLP synthesis genes, has proven effective at overcoming native strain limitations.

Strain heterogeneity adds a wrinkle. In the canonical GABA shunt, GABA transaminase catalyzes the conversion of GABA to succinic semialdehyde, feeding the tricarboxylic acid cycle in the degradative direction, meaning GABA serves predominantly as a nitrogen or carbon source rather than a biosynthetic intermediate. The reverse, biosynthetic direction would be thermodynamically unfavorable under physiological conditions. Yet Xie and colleagues demonstrated that in Lentilactobacillus curieae, a GAD-deficient strain, GABA accumulation depends upon GABA-T activity, as genetic deletion abolished and complementation restored production. Without flux data or cofactor characterization, the directionality remains speculative, and the review cautions that this GABA-T-mediated route should be regarded as a strain-specific metabolic curiosity rather than a universally conserved alternative pathway, underscoring the need for strain-specific screening before industrial application.

On the physiological side, the review assembles striking preclinical evidence. In a chronic restraint stress mouse model, oral GABA at 20 mg/kg raised prefrontal cortex GABA levels, reversed stress-induced complement system dysregulation, and upregulated IL-10 and TGF-β1 expression, suggesting anti-anxiety effects involve both classical GABAergic neurotransmission and neuro-immune interactions. GABA from Lactococcus lactis ZFM559 at 99.47 percent purity relieved depression-like behaviors by suppressing HPA axis hyperactivity, reducing inflammation, and modulating serotonergic metabolism. In metabolic contexts, GABA reduced serum ALT levels by 57 percent and hepatic triglyceride content by 39 percent in fructose-induced fatty liver mice, while GABA-fortified wheat bran reversed high-fat diet-induced insulin resistance in rats through hepatic PPARγ pathway activation. In pancreatic tissue, GABA promotes β-cell proliferation and modulates insulin and glucagon secretion balance, improving blood glucose homeostasis in diabetic mice.

The anti-inflammatory and barrier-protective functions extend the systemic picture. In macrophages and Kupffer cells, GABA acts through GABAA and GABAB receptors to suppress TLR4/NF-κB signaling and reduce pro-inflammatory cytokine production including IL-1β and TNF-α. GABA-treated mesenchymal stem cells reduce TNF-α secretion by approximately 75 percent. In a mouse model of dextran sodium sulfate-induced colitis, oral GABA at 40 mg/kg for seven days significantly attenuated disease severity, reducing colon permeability and suppressing TNF-α, IFN-γ, and IL-12 while increasing IL-10. In snakehead fish, dietary GABA at 60 to 120 mg/kg over 56 days dose-dependently improved intestinal mucosal barrier function, upregulating tight junction proteins such as occludin, claudin-4, and ZO-1. These findings operationalize the gut-brain axis hypothesis at the level of specific molecular interactions.

Yet the review is refreshingly honest about contradictions. Some studies found GABA treatment may increase susceptibility to dextran sodium sulfate-induced colitis, and lower GABA content in lychee fermentation products showed stronger protective effects on colon tissue. These discrepancies may reflect hormesis, biphasic dose-response, matrix synergy with other bioactives such as polyphenols, or species-specific receptor differences. GABA’s immune effects are context-dependent, varying with dose, tissue milieu, metabolites, and disease stage, rather than being inherently pro- or anti-inflammatory. Stratifying these factors is critical for safe GABA-enriched food development, and the fermentation conditions that favor GABA production also promote biogenic amine formation in certain strains, with histamine and tyramine accumulation potentially undermining the antihypertensive effects observed in preclinical studies.

Safety and regulatory frameworks exhibit considerable heterogeneity. Health Canada recommends a daily intake of 50 to 3000 mg, not exceeding 750 mg per single dose, while China’s national standard specifies a maximum daily intake of 500 mg as a new food resource. A 13-week oral toxicity evaluation in rats administered GABA at doses up to 2500 mg/kg body weight per day demonstrated no test substance-related mortality or toxicologically significant alterations. However, as the principal inhibitory neurotransmitter, GABA exerts dose-dependent pharmacological effects on the central nervous system, and excessive intake may theoretically potentiate CNS depression, particularly when co-administered with other GABAergic agents such as alcohol, benzodiazepines, or antihypertensive medications. Susceptible subgroups including pregnant women, paediatric populations, and individuals with compromised hepatic function require heightened vigilance.

Applications across food matrices demonstrate remarkable versatility. GABA-rich yogurt developed using Levilactobacillus brevis CGMCC 1.5954 achieved 147.36 mg per 100 mL, and anxiety and memory decline were significantly alleviated in mice with circadian rhythm disorders via the gut-brain axis. Legume-based beverages fermented with Lactiplantibacillus plantarum C9S2 achieve 2262.21 mg per liter. In fermented meats, Lactobacillus sakei CRL1756 converts meat-derived glutamate into GABA while producing distinctive nutty aromas. In cereals, germination combined with LAB fermentation maximizes content, though baking temperatures of 180 to 220 °C pose a significant threat, with studies indicating 40 to 60 percent degradation during conventional baking. Microencapsulation technology, especially when combined with probiotics, has proven effective at enhancing stability during processing and storage.

The review concludes with a sober assessment of translation. GABA concentration in a fermented food does not by itself guarantee a meaningful physiological outcome; the ultimate health effect depends on the dose consumed, bioavailability from the food matrix, stability during gastrointestinal transit, and absorption efficiency. Effective doses in preclinical studies often exceed those achievable through normal consumption of GABA-enriched foods, and blood-brain barrier permeability, species differences, and individual heterogeneity all limit direct extrapolation from animal models. Well-designed clinical trials remain necessary to establish the actual health benefits and underlying mechanisms of GABA derived from such products in human subjects. The convergence of food science and microbial engineering, including emerging computational tools, can build a complete value chain from GABA synthesis to food functionalization, advancing nutrition, innovation, and sustainability.

Subject of Research: Health-promoting functions of GABA and its biosynthesis by lactic acid bacteria for food industry applications

Article Title: The health-promoting functions of γ-aminobutyric acid (GABA) and lactic acid bacteria metabolism: From biosynthesis to applications in the food industry

Article References: Zhou, H., Yuan, W., Hu, J., Liu, M., Luo, J., Li, B., & Fan, X. (2026). The health-promoting functions of γ-aminobutyric acid (GABA) and lactic acid bacteria metabolism: From biosynthesis to applications in the food industry. Food Chemistry: X, Article 104627. https://doi.org/10.1016/j.fochx.2026.104627

Image Credits: AI Generated

DOI: 10.1016/j.fochx.2026.104627

Keywords: GABA, lactic acid bacteria, fermentation, functional foods, gut-brain axis, glutamate decarboxylase, probiotics, food science, microbiome, biogenic amines, health-promoting, functions